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ABSTRACT 
 
CHARACTERIZATION OF PROTEIN-PROTEIN INTERACTIONS FOR 
THERAPEUTIC DRUG DESIGN UTILIZING MASS SPECTROMETRY 
 
MAY 2015 
 
ALEX JOHNSON, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Igor A. Kaltashov 	  
The number of transferrin based therapeutics progressing to clinical trials remains 
disappointingly small despite promising capabilities of transporting therapeutic payloads 
to cancer cells and across the blood brain barrier. This meager success record is largely 
due to the complexity and heterogeneity of all protein conjugation products that generates 
difficulties for their analytical characterization. Discussed in this work, transferrin is 
conjugated to lysozyme as a model therapeutic to deliver this bacteriostatic protein to 
target central nervous system infections. In this work ESI- and MALDI-MS were used to 
characterize the modification sites at lysine residues in hopes of characterizing 
heterogeneity within the conjugate. Identification and quantization of modification sites 
using MS on tryptic digested samples proved difficult with poor signal to noise ratios and 
missing peptide fragments. The use of an 18O labeling method that exchanges both C-
terminal oxygen atoms with 18O provided more reliable results, but still proved difficult 
to observe all needed peptide fragments. MALDI-MS allowed for verification of ESI-MS 
results, but was found unhelpful with full characterization due to abundant overlapping of 
isotopic labeled peaks. Hoping to create an ideal 1:1 binding ratio between the two 
proteins, a site-specific modification method using kinetically controlled conditions was 
used and was confirmed that the method, although capable of producing 1:1 conjugated 
species, actually created different isomers with separate binding frequencies at each 
lysine. Online-IEC helped with the identification of isomers and started the initial work 
of correlating modification sites with bioactivity of the proteins. It was determined that 
lysozyme has a high chance of being modified at lysine 33 and 116, with a possibility of 
also being highly modified at lysine 97. More work is needed to complete the 
characterization, especially with transferrin, but the experimental approaches developed 
in this work prove to be promising. This work aims at delivering an optimized framework 
for analytical characterization of protein and antibody conjugates to guide the 
development of future biopharmaceuticals. 	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CHAPTER 1	  
  BACKGROUND/INTRODUCTION 
 	   A quite extensive library of promising novel therapeutic proteins and antibodies 
has been developed over the years. Improved ways in which to deliver these innovative 
agents has also been in the forefront of pharmaceutical research. Delivery of drugs can be 
enhanced by either changing the formulation or by changing the molecular structure of 
the medicine. Formulation manipulation may include colloidal systems, such as 
microspheres, and continuous release mechanisms, such as osmotic pumps, which can 
provide assistance compared to standard formulations. Modifying the molecular structure 
of a therapeutic, such as chemically adhering poly(ethylene glycol) [PEG] to the drug, 
can strengthen and protect the essential drug properties.1 While becoming potent and 
specific therapeutic agents, intrinsic limitations have delayed these novel drugs 
advancements. These shortcomings include susceptibility to destruction by proteolytic 
enzymes and immunogenicity.1,2,3,4 In order to overcome these limitations, PEG has been 
used to shield against these effects and create a conjugated protein. 	  
1.1 Polyethylene Glycol 
Frank F. Davis, a Professor of Biochemistry at Rutgers University, first conceived 
PEGylation in the late 1970s. As Davis was between grants, he became interested in 
developing a procedure whereby selected bioactive proteins could be utilized for human 
therapy. Davis decided to spend months in the university libraries to quench this new 
interest, until finally after reading a medical article his thought light bulb turned on.5, 6 
PEGylation has to be equipped with a reactive end group in order to attach to another 
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molecule. This attachment is achieved by targeting accessible amino residues, such as 
lysine or the N-terminus on the other molecule, and acts as a linker between two 
proteins.4,7  The shielding effect of the polymeric chains surrounding the protein of 
interest provides steric hindrance, preventing degrading enzymes from attacking and 
destroying the hopeful drug conjugate. PEG is FDA approved for usage as a vehicle or as 
a base in foods, cosmetics, and pharmaceuticals. PEG shows little toxicity and is disposed 
of intact by the body either through the kidneys, when PEG is less than 30 kDa, or in 
feces, when PEG is greater than 20 kDa.3  
 
Figure 1: Illustration of the structure of SM(PEG)12, which acts as the linker in a 
conjugate. 
 
Linking a carrier protein to a drug by using PEG introduces new challenges based 
on the heterogeneity and complexity of the conjugation, leading to difficulties in 
analytical characterization. The association of the two proteins can cause negative 
conformational changes, resulting in the interference with receptor binding, which can 
lead to a decrease in effectiveness in bioactivity. If binding a protein to another protein 
near either of their activation sites, the molecule may fail to be able to perform its normal 
function. One problem that may start to arise by attaching proteins using PEG is the 
possibility of attaching too many. This brings about the concept of DAR, which stands 
for drug-to-antibody ratio. This ratio is as it sounds; the average number of drug 
molecules covalently attached to the antibody or protein of interest. This ratio is 
important because drug designers need to anticipate how many drugs are attached to their 
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carriers to keep the efficacy and patient safety in check. It has been noted that the length, 
location, and number of PEG’s attached to a specific protein can change its biological 
activity from 6% to 40%.7, 8 Understanding the dynamics and characterization of 
conjugated therapeutics is extremely important and essential in optimization of drug 
design.	  
1.2 Transferrin 
There are many creative combinations being developed in therapeutic research 
these days. The research described in this thesis is specifically looking into the 
combination of Transferrin (Tf) conjugated to Lysozyme (Lz) via PEG linker as a model 
drug. Tf is a promising drug carrier due to its ability to safely deliver metals or 
therapeutic proteins throughout the body and across physiological barriers. Transferrin is 
a glycoprotein containing 679 amino acid residues and has a molecular weight of 79 kDa, 
remaining stable by its 19 intra-chain disulfide bonds. Transferrin has two evolutionary 
related lobes, the N-lobe (336 amino acids) and the C-lobe (343 amino acids), which are 
linked together by a short spacer sequence. Each of these lobes contains two domains 
comprising of a series of α-helices, which overlay a central β-sheet backbone. The 
interactions of these domains form a deep, hydrophilic metal ion-binding site.9  
Iron is the second most abundant metal in the earths crust and plays an extremely 
important role in living organism. Iron ions have the ability to strongly bind oxygen and 
play a central role in DNA replication. However, free iron can be toxic, promoting free 
radical formation resulting in oxidative damage to tissues. The two lobes of transferrin 
are capable of binding one iron atom; therefore each transferrin molecule (apo-Tf) can 
transport one (monoferric Tf) or two (diferric Tf) iron atoms. Transferrin is vital in living 
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organisms to ensure that iron is transported in a redox-inactive form since ferric iron 
(Fe3+) is the predominant state under aerobic conditions.10 The binding site for both the N- 
and C- lobes have four conserved amino acids (N-lobe – Asp-63, Tyr-95, Tyr-188 and 
His-249) arranged in an octahedral arrangement that, with the help of two oxygen 
molecules donated by a carbonate molecule and surrounding amino acids, stabilize the 
iron atom.9 Surrounding amino acids Lys-206 and Lys-296, which are located on 
opposite domains of the N-lobe, are shown to form hydrogen bonds when in the “closed” 
iron-bound state and when the pH is reduced to 5.5, the bond is broken and the iron is 
released from transferrin. 9 Iron loaded transferrin will seek out its particular transferrin 
receptor (TfR) on the surface of cells. 
 
 
Figure 2: Illustration of the RMT pathway. Iron binds to Tf in a diferric fashion in order 
to bind to its receptor. Once bound, the complex is engulfed in an endocytic vesicle and 
fuses with an endosome, where it is then transcytosed to the brain.11  	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1.3 Transferrin Receptor 
  The transferrin receptor is a cell membrane associated glycoprotein involved in 
the cellular uptake of iron by internalization of Tf through transcytosis. The transferrin 
receptor is ubiquitously expressed at low levels on normal cells and expressed at greater 
levels on cells with a high proliferation rate such as the basal epidermis, intestinal 
epithelium, and cancerous cells. Much Tf therapeutic research is based on attaching 
toxins to Tf is hopes of targeting the cancerous cells that show high levels of Tf activity.12 
Numerous studies have shown elevated expression of TfR on cancerous cells compared 
to normal cells, which could be explained by the need for iron as a cofactor of the 
ribonucleotide reductase enzyme involved in DNA synthesis of rapidly dividing cells.13 
There are at least two types of transferrin receptors that Tf can bind to. Transferrin 
receptor 1 (TfR1) is expressed on a wide array of cells ranging from red blood cells to 
erythroid cells to the blood-brain barrier. Transferrin receptor 2 (TfR2) is expressed as 
two transcripts that are mostly expressed on the liver cells and other variety of cells at 
low levels.9 The research conducted will focus on the intake of Tf using TfR1’s across 
the blood-brain barrier.  	  
1.4 Blood-Brain Barrier 
The blood-brain barrier (BBB)14,15 protects the central nervous system by 
regulating brain homeostasis through the control of entry of compounds into the brain. 
The barrier is formed by the endothelial cells of the brain capillaries and acts as a natural 
defense restricting clearance of harmful compounds to the brain, while allowing nutrients 
essential for normal metabolism to reach brain cells. Without this barrier, uncontrolled 
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neural activity would run rampant with the frequent small fluctuations brought on by 
changing levels of substances such as hormones and ions.16 Virtually, 100% of large 
molecules (mw > 1 kDa) and approximately 98% of all small molecules are denied 
passage through the blood-brain barrier.17 This fact is one of the few aspects limiting the 
development of new central nervous system (CNS) medicines and is quite discerning 
since one out of every three individuals will acquire a CNS condition during their 
lifetime.18 Current methods of treating CNS conditions are invasive, dangerous, and 
sometimes ineffective. Such treatments are direct intracranial injection, intraventricular 
administration, and BBB disruption.14 The research conducted concentrates on using a 
non-invasive procedure to help treat CNS conditions by utilizing the transport systems 
that allow larger molecules, such as transferrin, to enter into the brain.  	  
1.5 Receptor-Mediated Transcytosis 
 Receptor-mediated transcytosis (RMT) allows the transport of larger molecules to 
pass through the blood-brain barrier by means of vesicular trafficking mechanisms of the 
endothelium. This transport system, depicted in figure 2, can be utilized to carry 
conjugated therapeutic agents non-invasively into the brain that would otherwise be 
excluded by the blood-brain barrier. Iron is one of the essential nutrients needed for a 
healthy brain. First coming into contact with transferrin to form diferric Tf, this fully 
closed state Tf seeks out a transferrin receptor for binding on the apical plasma 
membrane. Once Tf is bound to the TfR1, the encapsulation of the Tf-TfR complex in a 
clatherin-coated vesicle is initiated by the invagination of the membrane. With normal 
endocytosis, the decrease in pH in the endosome triggers a conformational change in 
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transferrin, subsequently releasing the iron and increasing the affinity of apo-Tf for the 
receptor. The Tf-TfR complex is returned to the cell surface, releasing Tf to once again 
find iron to repeat the process.13,14 With transcytosis, the receptor is not recycled back to 
the cell surface, but instead passes through the BBB along with the conjugated Tf. The 
process of transcytosis is not completely understood, but experiments have shown that up 
to 50% of transferrin receptor-mediated uptake is carried out by transcytosis.19 While this 
process sounds ideal for a non-invasive therapeutic delivery system, Tf is a difficult 
delivery vector since its receptors are frequently saturated with endogenous transferrin 
that circulates throughout the bloodstream at a concentration of 25mM; meaning 
competition for the receptor would take place between a drug conjugated Tf and natural 
Tf. There could be ways of inhibiting the release of Tf, thereby enhancing the 
transcytosis process. It has been noted that a low fraction of about 1-4% of injected doses 
actually reach the brain, but this low percentage is still sufficient enough to treat CNS 
condition.14 	  
1.6 Lysozyme 
 A particular protein of interest in which to bind to transferrin for a model drug 
conjugation is lysozyme (Lz). Lysozyme is alluring in this linkage with Tf for its 
bacteriostatic properties against gram-positive and gram-negative bacteria.20 Lysozyme is 
a lytic enzyme discovered in 1921 by Sir Alexander Fleming, the same scientist who 
received the 1945 Nobel Prize for the introduction of penicillin. Lysozyme was the first 
enzyme containing the varied amino acids to be sequenced in 1963 and the first whose x-
ray crystallographic analysis and reaction mechanism was achieved.21 Being the first is 
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why lysozyme is one of the most characterized and modeled enzymes in biochemistry. 
Lysozyme can be found throughout the body, with particularly large concentrations in 
human serum; but there is no lysozyme found in cerebrospinal fluid (CSF). 22, 23, 24 Studies 
suggest that detectable levels of lysozyme in CSF correlate to assorted CNS pathologies 
when the BBB is disrupted and becomes leaky, allowing free access for species otherwise 
denied passage.22, 25 There are almost 100 lysozymes sequenced, but the major type used 
in research today is chicken-type, which comes from hen egg white and is easily obtained 
in high quantities. Lysozyme is a small compact protein weighing 14,307 Da consisting 
of 129 amino acid residues held together mostly by four disulfide links. The structure has 
a mix of alpha and beta folds with a deep active site cavity. Lysozyme uses this active 
site to hydrolyze the β-1, 4-glycosidic bond between N-acetylmuramic acid 
(MurNAc/NAM) and N-acetylglucosamine (GlcNAc/NAG) residues, the components 
that make up a bacterial cell wall.21, 26  
 Since the introduction of antibiotics, the number of harmful pathogens with 
resistance to these medicines has increased, leading to the creation of so called 
superbugs. These superbugs have brought attention to scientists to seek out new 
antimicrobial medicines to destroy the pathogens in a new manner. In consideration are 
large biologically influenced host defense systems, such as amphiphilic peptides and 
bacteriostatic proteins.26, 27 Lysozyme is considered one of these bacteriostatic proteins 
with its ability to lyse cell walls. 	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1.7 N-Succinimidyl S-Acetylthioacetate 
 PEG is used in order for transferrin to conjugate to lysozyme, but in order for the 
conjugation to work, there must be another linker attached to the protein of interest to 
link to PEG. Lysozyme can use N-Succinimidyl S-Acetylthioacetate (SATA) to complete 
the conjugation. SATA is a reagent used to introduce protected sulfhydryls into a protein 
when thiols are unavailable or absent. It works by covalently forming an amide bond 
from the reaction of the N-hydroxysuccinimide ester with primary amines of the protein 
of interest. Deacetylation, also known as deprotection, then occurs using hydroxylamine 
to generate a sulfhydryl to be used in the cross-linking.28, 29 This allows the completion of 
SATA to link with PEG for the conjugation of transferrin to lysozyme.  
 
Figure 3: Illustration of the structure of SATA, the reagent used to modify Lz.  
 
1.8 Solving the problems 
 As mentioned earlier, designing a novel drug is quite exciting, but developing this 
therapeutic to reach final stages can be difficult. The issues of premature degradation by 
proteolytic enzymes, immunogenicity, and delivery mechanism can be solved by the use 
of PEG to conjugate drugs to carrier proteins. Using conjugation to resolve those issues 
starts to create new difficulties, such as steric hindrance and the dug-to-carrier ratio, 
which in turn may cause new problems with receptor binding affinity, bioactivity, and 
efficacy. This study searches to develop and provide important feedback through 
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experimentation for the refinement and optimization of conjugate drug design. The model 
therapeutic used in this research is transferrin PEGylated to lysozyme using SATA as a 
linker.  
 
Figure 4: The schematic for creating the Lz-Tf conjugate. Tf is PEGylated and Lz is 
modified with SATA. Side products that could be created are dimers.26 
 
Having the ability of transferrin to deliver lysozyme across the BBB could lead to 
the development of therapeutic strategies with the goal to cure infections in the central 
nervous system in a non-invasive fashion. The ideal concept is to have the internalization 
of Tf through the binding of its receptor on the BBB in order to release Lz on the 
basolateral side of the barrier. Lysozyme will then target the pathogens and lyse the cell 
walls. To help find some answers to these new challenges, this study utilized the 
capabilities of a few instruments and methods to help characterize the number of bound 
drugs and their locations within the conjugation.  
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CHAPTER	  2	  
INSTRUMENTATION 
2.1 Mass Spectrometry 
 Mass spectrometry is a method in which a mass-to-charge (m/z) ratio is 
determined in order to reveal the mass of a particular sample being analyzed. A mass 
spectrometer is an instrument that produces ions using an ionization source to then 
separate the charged species according to their mass-to-charge ratio by a mass analyzer. 
A mass spectrum consists of a plot of ion abundance versus mass-to-charge ratio and is 
presented in terms of Daltons (Da) per unit charge. Mass spectrometric analysis involves 
three main components: an ionization source, a mass analyzer, and a detector.  
 Mass spectrometry analyzes samples in a charge gaseous phase, so an ionization 
source is needed. In the past, samples had to first be volatilized and then ionized to be 
analyzed, but this limited the types of samples that could be analyzed to low molecular 
weight compounds that were thermally stable.30 Advancements in ionization techniques 
has allowed the analysis of large, non-volatile and thermally labile compounds to be 
investigated. The source mainly utilized in this research is an electrospray ionization 
source.  
 The detector inside a mass spectrometer measures the ions and transforms this 
information into an electrical signal that can be relayed to a computer for user analysis. 
The detector, which is usually an electron multiplier, works by having dynodes held at 
successively higher voltages. Once energetic ions strike the surfaces of the cathode and 
dynodes, bursts of electrons are emitted that are attracted to the next dynode down a 
chain of dynodes, until the last one is reached where a large amount of electrons appear 
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for every ion that strikes the cathode.31 The relay of electrons is then analyzed and 
converted to a signal for the computer to interpret for the user. There are different types 
of mass analyzers that measure ions in different ways. The most significant aspects of a 
mass analyzer are its accuracy and precision. Precision of the measurement is associated 
with the resolution of adjacent peaks, usually defined as m/Δm, where m is the integer 
mass of the peaks being resolved and Δm is the mass difference between the two peaks.30 
The analyzers used mostly in this study were quadrupole coupled with time-of-flight. 
2.2 Quadrupole  
 The most common type of mass spectrometer used in quadrupole. The guts of a 
quadrupole instrument are the four parallel cylindrical rods acting as the electrodes. 
Opposite rods are linked electrically, with one rod acting as the positive side of a variable 
dc source and the other acting as the negative terminal. In addition, variable radio 
frequency ac voltages, which are 180o out of phase, are applied to each pair of rods.31 
Ions are accelerated through the middle of the four rods and at the same time the ac and 
dc voltages on the rods are increase while staying at a constant ratio. At any given 
moment, all of the ions except those having a certain m/z value strike the rods and lose 
their charge, becoming neutral molecules, allowing ions having a limited m/z value range 
to reach the transducer.31  
2.3 Time-of-flight 
 A time-of-flight (TOF) spectrometer works by separating ions based on their 
velocities through the drift tube. Ideally, all of the ions are formed at the same time and 
place in the ion source and are then accelerated through a fixed potential into the TOF 
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drift tube.30 Once within the tube, ions with the same charge accelerate at the same rate, 
with low m/z ions achieving higher velocities than the higher m/z ions, all at an inverse 
relationship of the square root of the ions m/z.30 After accelerating through the tube; they 
hit the detector at different time points based on their flight path allowing the m/z to be 
determined. More sophisticated TOF instruments include a reflectron, which allows the 
ions to travel farther by forcing them to make an almost 180o turn allowing a longer flight 
path to increase resolution because of greater separation between close m/z ions.  
2.4 Electrospray Ionization 
 As little as thirty years ago, the idea of making proteins or polymers “fly” by 
electrospray ionization (ESI) seemed as improbable as a flying elephant, but modern 
techniques have allowed Dumbo to take flight and become a standard part of mass 
spectrometry and one of the most important techniques used for analyzing 
biomolecules.32 In the 1980’s, this soft desorption ionization method was conceived from 
the minds of two chemists, John Fenn and Koichi Tanaka, while searching for a method 
that could become the hyphen between LC-MS. Electrospray ionization is performed 
under atmospheric pressures when a solution of sample is injected through a stainless 
steel capillary needle at low flow rates of around a few micro liters per minute. The 
needle sustains a current ranging from several kilovolts with respect to a cylindrical 
electrode that surrounds the needle. This voltage creates a charged spray of fine droplets 
that passes through a desolvating capillary; where evaporation of the solvent and 
attachment of charge to the analyte molecules takes place.31 The droplets then 
subsequently shrink just before entering into the mass spectrometer.  
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Figure 5: Electrospray ionization illustration. A voltage is transferred from the capillary 
to the sample. As the sample moves towards the mass spectrometer, desolvation occurs 
leading to multiply charged species to be analyzed. 	  
 As the sample proceeds to exit the needle, the liquid conforms into a conical 
meniscus known as a Taylor Cone. A Taylor Cone is essentially a buildup of charge at 
the tip of the needled caused by the created electric field, shaping the liquid into a cone 
figure developed by the surface tension and viscosity.33 As the charge on the needle starts 
to increase, the cone begins to jet outwards until it starts to break at its weakest point, 
forming charged droplets  
 As the droplets move towards the mass analyzer, a progression of evaporation 
steps lead to smaller and smaller droplets (Figure 5). As solvent evaporation occurs from 
a charged droplet, the surface field increases until the Rayleigh limit is reached. At this 
point, the coulomb repulsion is of the same order as surface tension. The resulting 
instability disperses the droplet into a cluster of smaller droplets, sometimes known as a 
“coulomb explosion”.32, 34 The droplets continue to evaporate until ultimately each droplet 
is so small that it only contains a single solute molecule. The solute molecule preserves 
some of it’s droplets charge to become a free ion as the rest of the solvent vaporizes.  
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 Electrospray ionization mass spectrometry has provided scientists with the ability 
to analyze higher-molecular-weight molecules because of its ability to create multiple 
charged species. This method allows non-covalent biomacromolecular complexes to be 
ionized intact and has the ability to be combined with liquid separation techniques, such 
as ion exchange chromatography.30  
2.5 Matrix Assisted Laser Desorption Ionization  
 Matrix assisted laser desorption ionization (MALDI) is another soft ionization 
method widely used to characterize large biomolecules. As implied in the name, MALDI 
uses a laser to bombard the sample to produce singly charge molecular ions. While ESI 
produces ions continuously, MALDI ions are produced by pulsed-laser irradiation of the 
sample, which is mixed and co-crystallized with a highly absorbing matrix on a steel 
plate. The more commonly used matrices are sinapinic acid, for protein analysis, and 
alpha-cyano-4-hydroxycinnamic acid (CHCA), for peptide analysis. The solvent used 
usually contains trace amounts of trifluoroacetic acid (TFA) to induce positive ionization. 
The matrix takes the energy from the laser pulse and transforms it into excitation energy 
for the sample, which creates a small plume of singly-protonated analyte and matrix ions 
from the steel plate. While under high vacuum, the ions usually go through a time-of-
flight analyzer and are separated based on their mass-to-charge ratios. As with any 
method, there are favorable and flawed attributes. MALDI is terrific for conserving 
sample since it uses a pulse ionization instead of continuous flow, thereby little sample is 
wasted and high levels of sensitivity is achieved.30 MALDI is also excellent in respect to 
time, allowing high throughput to analyze multiple samples in a short span of time. Some 
problems that come with the method has to do mostly with viewing ions in the spectrum. 
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The matrix causes a large amount of chemical noise at the low m/s range, hindering the 
ability to view low molecular weight samples. The method is quick and easy to interpret 
with its ability of producing singly protonated species, but this can cause a problem with 
performing peptide analysis or proteins of similar size because it can cause overlapping 
and difficulty identifying masses.  
2.6 Analyzing a mass spectrum 
 Before the age of computers, scientists would physically calculate their results 
with pen and paper. Today, the ability of scientists to interpret their own results without 
the use of computer software is just as critical. A quick way to analyze a multiply 
charged mass spectrum is to use the given m/z values to calculate the charge state and 
approximate mass to help identify an unknown sample. To start the calculation, two 
adjacent peaks on the spectrum must be chosen, remembering that the difference between 
two peaks is one proton. The equation is as follows, where M = mass of sample, Z = 
charge state, and m/z is the peak value.  
For the left peak, which has an extra proton: 
ML + (Z+1) x 1 = m/z 
    (Z+1) 
Then solve for M in terms of Z: 
ML + Z + 1 = (m/z) Z + (m/z) 
ML = (m/z – 1) Z + (m/z – 1) 
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Next go to the right peak, which does not carry that extra proton, to later be compared 
with the M value for the first peak: 
MR + Z x 1 = m/z 
                Z 
 
MR + Z = (m/z) Z 
MR = (m/z – 1) Z 
Then can compare both of our M values to solve for the charge state of the right peak: 
ML = MR 
(m/z – 1) Z + (m/z – 1) = (m/z – 1) 
Solving for Z in the equation above once the the charge state is known, solving for the 
mass of the sample can be done by plugging in the Z value into the next equation: 
M + Z = (m/z) Z 
The mass will then be in units of Daltons (Da). 
2.7 Tandem Mass Spectrometry 
 Tandem mass spectrometry (MS/MS) has been another key contributor in the 
advances of therapeutic research. A tandem mass spectrometer uses two analyzers 
separated by a collision cell where inert gas collides with the selected sample ions to 
bring about fragmentation and produce structural information for peptide mapping. The 
first analyzer isolates ions of a desired m/z, which are termed the parent or precursor 
ions. These ions are then induced to undergo chemical reaction that changes either their 
mass or charge, leading to dissociation. These resulting ions are known as product ions, 
and are then monitored by the second analyzer.28 Three different types of bonds can 
fragment along the amino acid backbone: the NH-CH, CH-CO, and CO-NH bonds, as 
	  18	  
seen in Figure 6A. This fragmentation creates a charged and neutral species, where the 
charged species is the one to be analyzed by the spectrometer. The most commonly 
cleaved bonds are the CO-NH bonds. The charge can attach to either of the two 
fragments depending on the proton affinity; therefore six possible fragment ions can 
exist. If the charge is retained on the N-terminal fragment, a, b, and c ions are created; 
and if the charge stays with the C-terminal fragment, x, y, and z ions are produced. The 
difference between two adjacent ions is equal to the specific amino acid residue weight. 
An example can be seen of a Lz fragment that was digested with trypsin and analyzed in 
Figure 6B. Observing that adding or decreasing the mass of each amino acid created b 
and y ions, the next peak will is that distance away.  
 
Figure 6: Illustrated are the fragmentations that can occur when using mass spectrometry 
(A) and an example of how MS2 data is analyzed (B) using a peptide fragment of 
modified Lz. The asterisk between the lysine and arginine residue signifies a modified 
lysine residue. 
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2.8 Ion-Exchange Chromatography 
 Ion-exchange chromatography (IEC) is a practical technique used to separate 
species based on their charge. Ion exchange separation methods have been around since 
the first ion exchange resins were developed back in the 1930’s, but the modern 
technique was not practiced until the middle of the 1970’s, when high performance liquid 
chromatography showed anion or cation mixtures could be resolved on resin packed 
columns using the instrument.31 Ion chromatography started with the development of 
separating rare earth cations with a cation-exchange resin for the research on the 
Manhattan project. The technique advanced to include the separation of other metals after 
World War II; which ultimately led to the detection and separation of amino acids and 
other ionic species found in complex mixtures.31 Historically, ion-exchange 
chromatography was performed on small, porous beads that formed during emulsion 
copolymerization of styrene and divinylbenzene. These stable pores were then active 
towards ions by bonding functional groups to the cross-linking structure. While the 
packing performed the job of separating species, the process was slow; so two newer 
types of packing materials were developed. The first is polymeric bead packing, where 
the surfaces of the beads are coated with a synthetic ion-exchange resin and have a 
relative high capacity. The second type gives higher efficiencies and is prepared by 
coating porous microparticles of silica with a thin film of exchange resin.31 There are two 
modes of IEC, cation exchange and anion exchange. In cation exchange, positively 
charged molecules are attracted and retained to the negatively charged solid support 
found in the column. The opposite is true with anion exchange, where the negatively 
charged species are retained to the positively charged stationary phase. The method 
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works by injecting the sample into the column and having a mobile phase of low 
conductivity wash through the initial species that are not retained by the stationary phase. 
The molecules are retained to the oppositely charged support until the mobile phase gains 
ionic strength and elutes the species out in order of their overall interactive strength with 
the functional groups on the stationary phase. In order for the mobile phase to elute the 
sample from the column, a type of gradient should be applied that varies the salt 
concentration or pH. By increasing the salt concentration, the molecules with weaker 
ionic interactions will elute out first, leaving the stronger ionic interactions to elute out 
later. By varying the pH, such as raising the pH to a more basic mobile phase, a cation 
exchange column will have the molecules become less protonated and less positively 
charged, allowing them to elute off of the negatively charged column. In principle, 
species can be separated based on their isoelectric point (pI), which is the pH at which the 
molecule holds no net charge, allowing it to have little to no interaction with the charged 
column.  
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CHAPTER 3 
PAST STUDIES 
 The main source of background knowledge for conducting this research came 
from the past work of many scientists around the world. Research done on related 
lysozyme PEGylated therapeutic studies have been conducted by Lee et al. at the Korea 
Advanced Institute of Science and Technology and Maiser et al. at the Karlsruhe Institute 
of Technology.7, 35 Research consisting of transferrin conjugation has been done by 
Peppas et al. at the University of Texas Austin.36 This particular study came from the 
initial work of Son Nguyen in the Kaltashov laboratory at the University of 
Massachusetts Amherst.26  
As aforementioned, identification of binding sites is critical in the characterization 
of conjugated therapeutic proteins. The study performed by Lee et al., presented a process 
for identifying PEGylated sites on their model protein lysozyme by using an avidin-biotin 
interaction and MALDI-TOF mass spectrometry. Using a PEG derivative, biotin-PEG-N-
hydroxyl succinimide (NHS), conjugated to lysozyme; tryptic digestion was performed 
and fragments were separated using avidin affinity chromatography. Fractions of these 
peptides were analyzed by MALDI and RP-HPLC to determine the respective binding at 
the different lysine sites. In their work, Lysozyme and biotin-PEG-CO2-NHS were 
dissolved in 0.1 M Tris-HCl, pH 8.0 and left at 4°C for 10 hours. Acetic acid was added to 
terminate the reaction, adjusting the pH to 4.2, followed by the solution being dialyzed. 
The conjugated lysozyme was then analyzed by SEC using an isocratic mobile phase of 
50 mM Tris-HCl, pH 8.0 with a flow rate of 0.8 mL/min with detection at 280 nm to 
collect mono-PEGylated lysozyme. The PEGylated lysozyme (6.3 mg) was then 
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dissolved in buffer and incubated with 6 M GuHCL and 10 mM DTT to reduce disulfide 
groups. Then to ensure there was no oxidation of the free thiol groups, 0.1 M iodoacetate 
solution was added and incubation occurred for 6 hours at room temperature. After 
dialysis, a solution of 50 mM Tris-HCl, 1 mM CaCl2, and 2 M urea was added at a weight 
ratio of 100:1 lysozyme to trypsin. The group had trouble fully digesting the peptides 
because PEG was causing resistance to enzymatic digestion with its steric repulsion. To 
purify the digested conjugates, a column packed with monomeric avidin was used, where 
avidin binds to biotin with a Kd of 10-7, allowing reversible binding of the biotinylated 
peptides under mild elution conditions (5 mM biotin). Separation of the biotin-PEGylated 
peptides was done RP-HPLC using a C-18 column with solvent A (0.1% TFA in H2O) 
and solvent B (0.1% TFA in ACN). Analysis of the peptides was then conducted using 
MALDI-TOF mass spectrometry with a matrix of sinapinic acid. The study identifies 
four different PEGylation sites (K33, K96, K97, and K116) based on predicted m/z 
values using tryptic digest mapping patterns of native lysozyme. The sites at K96 and 
K97 produced the same tryptic digestion profiles, so the MALDI method at the time 
could not fully differentiate the mass peaks of the two sites, but based on past studies, 
they concluded that K97 was more reactive than K96.  	  
 Using the RP-HPLC, they were able to estimate the relative fractional amounts of 
the three major PEGylated fragments, revealing that the order of reactivity was K33 > 
K97 > K116. This study was a great stepping-stone for researchers looking to 
characterize conjugated therapeutic proteins, but Maiser et al. were not satisfied and took 
this research a step farther in trying and characterize all of the lysine binding sites.  
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 The study done by Maiser et al. used MALDI-MS, as Lee had done before; but 
this time in the purification steps, ion exchange chromatography was utilized, allowing 
better separation of mono-PEGylated lysozyme. Lysozyme and mPEG-aldehyde were 
dissolved in 25 mM sodium phosphate buffer pH 7.2 containing 20 mM sodium 
cyanoborohydride as reducing agent at a protein to polymer ratio of 1:6. It should be 
noted that this group used a different PEGylation, where PEG-aldehyde readily reacts 
with N-terminal amine groups rather than the PEG-NHS mostly reacting with other 
amino groups, as in the case with Lee et al. This reaction was continuously shaken at 
room temperature for three and a half hours. The group used SEC to try and optimize the 
reaction time to produce higher yields of mono-PEG-Lz species. To collect mono-PEG-
Lz samples, IEC was used with 25 mM sodium phosphate, pH 7.2 and 25 mM sodium 
phosphate with 500 mM sodium chloride, pH 7.2. Size exclusion chromatography was 
then run again to ensure only mono-PEG-Lz was collected in the fractions. Once satisfied 
with the collection of purely mono-species, IEC was used to try to separate the 7 possible 
isoforms on the conjugation. They separately ran the samples through a pH gradient from 
10.5 to 11.5 and also a salt gradient from 0 mM to 500 mM NaCl. In their experiments, 
the salt gradient could only separate three isoforms. The pH gradient however worked 
splendidly for them, allowing separation of 5 out of the 6 isoforms, with the seventh 
being the N-terminal on lysine 1. Using the pH gradient allowed them to identify which 
lysine was being conjugated by means of calculating their individual isoelectric points 
(pI). The individual isoelectric points of the fragments were calculated by using a web-
based tool called protein continuum electrostatics (PCE) that calculates the pKa values of 
titratable groups in proteins by solving the Poisson-Boltzmann equation.37 As seen in the 
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sixth figure of the article; based on the pI values, the modified residues elute in the 
following order: Lys 33, 1, 96, 97 & 116 together, and lastly 13. The linearity between 
the calculated pI value and the eluted pH value was within 99%. 	  
 In order to verify the binding site identifications, they investigated the mass of the 
PEG-peptide fragments. Using MALDI-TOF MS, four PEG-peptide fragments were 
detected from the fractions collected during IEC by determining the average mass of each 
peptide. The MS spectrum of each PEG-lys peptide shows peaks separated by 44 Da, 
which is caused from the PEG chains with a different number of monomer units attached. 
The mass over charge value of the peptide fragments were calculated by taking the m/z of 
the two fragments that would not be cleaved if PEG was bound; for example, with Lys33 
which has peptides 22-33 (1325.63 m/z) and 34-45 (1428.65) flanking each side of the 
lysine residue, the addition of these peptides plus the m/z of the PEG (5,000 m/z) will 
give the correct m/z value.  
 It was not possible to prove through MS the third detected peak containing K96 
because there were no detectable PEG mass peaks due to low concentrations. The group 
only observed K116 in the fourth peak, which is supposed to hold both K97 and K116 
based on the same pI values. Validation of K13 could not be confirmed because they 
could not find the correct m/z value expected and even after some corrections for 
improper cleavage, the peptide still could not be validated. The group felt that their 
identification methods showed a good correlation and compared well with the results 
from a study done by Tilton et al, who used PEG-aldehyde and proposed a predominant 
N-terminal modification, which happened to have the largest abundance in their 
chromatogram as well.38  
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 Transferrin studies done by Peppas et al. explored the conjugation of insulin to 
transferrin by forming disulfide bonds in order to improve insulin oral bioavailability 
through the use of receptor-mediated endocytosis. Using ESI-MS, the group studied the 
modification of insulin when conjugated to Tf, the stability of conjugated insulin to 
degradation, and site-specific modifications of insulin. A heterobifunctional cross linker 
called succinimidyl 3-(2-pyridyldithio)propionate (SPDP) that reacts with primary 
amines and sulfhydryl groups was used to conjugate insulin to transferrin. When SPDP 
reacts with the accessible amine groups, a mixed disulfide with free 2-pyridyldithio 
groups forms and reacts with free sulfhydryl groups from the other protein, resulting in 
heteroconjugation without unwanted cross-reaction products. While no unwanted cross-
reaction products is great; the incorrect modification of insulin by DMMA, which blocks 
the N-terminal primary amines, allowing SPDP to react with the correct amines can 
diminish physiological activity. So the group used fluorescamine to quantify the number 
of free amino groups of insulin. The ideal insulin product should not react with any of the 
fluorophors, meaning that there are no free amino groups. While they showed that their 
reactions were producing what was wanted, this fluorescence assay couldn’t tell the 
locations of the reaction sites, so mass spectrometry was used to solve this problem. 
Using ESI-MS, they showed that there were 1:1 and 2:1 DMMA:insulin species with no 
3:1 ratio, which would signify nonspecific modification of insulin to the two N-terminal 
amines. Next they showed the 2:1:1 major product of DMMA/insulin/PDP using ESI-MS 
and decided to perform a tryptic digest on this species. There would only be one cleavage 
site for the insulin product, which produces a 43 amino acid peptide that contains both of 
the N-termini and an 8 amino acid peptide that contains the C-terminus and the PDP 
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attachment, if everything is bound to the correct sites. The smaller fragment’s spectra 
show a mass shift of 197 Da, indicating the presence of the PDP attachment. While this 
shows that the PDP is clearly attached to the specific lysine residue since there is non-
cleavage of that lysine, which would have produced a 7 amino acid peptide instead of the 
8 amino acid peptide. The group further proved its binding location by performing an 
MS3 experiment with the y4-PDP and the y2-PDP fragments, showing that the lysine was 
the sole site of PDP modification. To test the stability of the conjugate, degradation 
profiles were developed by using a trypsin solution and showed that the conjugate had 
increased stability compared to the insulin alone.  
 A bright PhD candidate named Son Nguyen, from the Kaltashov lab at the 
University of Massachusetts, accomplished the initial achievements for the research. His 
work explored the structure and interactions of lysozyme conjugated to transferrin as a 
model therapeutic that targets the central nervous system. The first portion of the study 
involved completing the chemistry of the conjugation. Following the classical scheme of 
conjugating Tf to a drug involves derivatizing the lysine side chains and amino terminus 
with sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate (sulfo-
SMCC) and then activating the payload, Lysozyme, by using Traut’s reagent (2-
iminothiolane hydrochloride). This scheme is suppose to ideally create a 1:1 
stoichiometry so the functionalization of each protein is maintained with minimal 
hindrance. The actual scheme created is incredibly difficult to control to just two single 
reactive groups on each protein. With transferrin having 58 lysine residues and lysozyme 
having 6, the amount of different possibilities for binding between the two proteins is 
enormous, and trying to manipulate the proteins to only bind at two specific locations is a 
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daunting task. While being able to produce sufficient yields of the conjugate, this was 
only achieved if multiple activation groups were placed on both proteins. Creation of 
undesirable side reactions and homopolymerization due to these multiple attachments 
contributes to the heterogeneity of the conjugates. In order to try and minimize the 
unwanted products, Nguyen altered many variables and used mass spectrometry to 
optimize the yield of wanted conjugates.  
 The first variable looked at was the modification reagent. Traut’s reagent started 
to create problems by forming dead end products of N-substituted 2-iminothilane (NSI) 
and with the reduction of intramolecular disulfide bonds. Using Traut’s reagent with Tf 
lead to unexpected reduction of the native disulfide bonds leading to deleterious 
conformational changes in the higher order structure. This problem was seen in Lz as 
well, but was easily deterred by reducing the concentration and conducting the reaction 
on ice. As stated above, the reagent started to produce nonreactive products when the 
unstable thiol adduct broke down into a nonreactive 5-membered ring and reduced the 
number of free thiol groups; which can cause problems with downstream conjugation. 
Overcoming this obstacle was accomplished by substituting Trauts reagent with SATA, 
which was found to increase stability and reduce heterogeneity.  
 The next variables tested focused on trying to optimize reactions and reducing 
unwanted byproducts. Using ESI-MS, screening included changing the pH from 7.0 to 
9.0, temperature from 0 to 37 °C, reaction times from 0.5 to 24 h, and ratios of protein to 
reagent from 2:1 to 1:4. The final optimized conditions for Lz were performed at pH 8.0, 
0 °C, for 12 hours at an equimolar ratio. Transferrin was found to be optimized at pH 7.0, 
25 °C for 90 minutes using 50 μM at a 1:2 ratio. While individually optimized, the Lz-Tf 
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conjugate was then screened and found to have the highest yield at pH 7 at 4 °C for half a 
day. Even after all of the optimization, a large number of other species can be seen in the 
mixture, so products must be separated from other products and reagents. SEC was 
thought of, but proved impractical at this stage because of the incremental mass increase 
of Lz-Tf over intact Tf.  
 A different way of separating the species is based on their pI values, with Tf 
having a pI value of 5.5-6.3 and Lz having its value at 11.0. Using weak cation exchange, 
the Tf, Lz and Tf-Lz species were all separated and after fraction collection and desalting, 
the ESI-MS confirmed each of the species. Amongst the details found by using ESI-MS, 
neither protein underwent partial or complete unfolding, but this does not totally mean 
that the proteins are unaffected when it comes to their abilities to properly bind to their 
partners. Native ESI-MS has allowed the research group to analyze Tf and its partner 
receptors and its relative binding affinity. From the spectrum below in figure 7, it is clear 
that the Lz-Tf conjugate is still capable of binding to the TfR, but at a lower affinity than 
intact Tf.  
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Figure 7: ESI mass spectra of Tf/TfR (A) and Lz-Tf/TfR (B) at neutral pH, 20 mM ionic 
strength.26 	  
 From the spectra, there is noticeably little to no ionic signal for the unbound 
Fe2Tf, which is expected from the receptor-binding affinity of Fe2Tf being in the sub-μM 
range. Then by observing the ionic signal that is detected from the unbound Lz-Tf in 
spectra B, it is concluded that the TfR binding affinity for the conjugate is in the low-μM 
range. Even though the affinity is lower, it still should be sufficient enough for the 
binding to occur and could become beneficial for the dissociation after passing through 
the BBB. From this experiment, it is certain that the conjugate will bind to the receptor, 
but the next experiment has to test whether the drug, or in this case the lysozyme, will 
still perform its proper function and exhibit its bacteriostatic properties.  
 In order to determine the enzymatic functionalization of Lz is still intact, a short 
trisaccharide NAG3 is used as a surrogate substrate to show the substrate binding 
capabilities. Even with the non-specific binding of reagent near or far from the catalytic 
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site of Lz, the Lz-Tf conjugate still has the ability to bind NAG3, which can be seen in the 
mass spectrum below in figure 8 by the presence of the protein-NAG3 complexes.  
 
Figure 8: ESI mass spectra of NAG3/Lz-Tf at near-native conditions.26 
 
While the substrate binding capability experiment was promising, results from a 
photometric-based activity assay that measures the lysis of Gram-positive bacteria shows 
that there is a significant decrease in bacteriolytic activity of the conjugate. This assay 
can be seen in the article, where intact Lz and Tf are compared to conjugates as well as 
Lz dimers. It is hypothesized that the reduction of activity may be due to either change in 
electrostatic properties on the surface that may cause a conformational change near the 
catalytic site or that the large protein within the conjugation may be causing steric effects, 
making it difficult for the Lz to attack the cell wall. The results concluded that the Lz 
dimer is reduced 4-fold compared to intact Lz and after adjusting for having two catalytic 
sites, it was reported as 18.6%. This lysozyme dimer byproduct proves important to show 
that the while reagent modification of the protein contributes to the reduction in activity, 
it is not the sole contribution to decreased activity. This assay primarily showed that the 
inactivity is largely contributed to the steric restraint caused by the bulky anchor protein 
Tf. With this being the case, the thought of using a longer linker between the two proteins 
should decrease the hindrance and allow more movement for the Lz to attack cell walls 
	  31	  
more efficiently. An amine-reactive SM(PEG)12 was used to activate Tf and introduce 
free thiol groups to Lz still using SATA. With this new scheme, the conjugate was 
recognized by the TfR and had over a full order of magnitude higher Lz activity than the 
old scheme. In a perfect world, correlation between the location of linkers in the 
conjugation and the bioactivity of the conjugate can be monitored for the optimization 
during the design of future protein conjugates. Since there is likely a correlation between 
the location of the linker and the activity of the conjugate, identifying specific sites of 
conjugation by the use of mass spectrometry became the future focus of Nguyen’s initial 
study and has become the current work detailed in this thesis.  
 The goal of this whole study is to provide important feedback through 
experiments to use in the refinement and optimization of conjugate drug development. To 
achieve this goal, SATA will be used to modify lysozyme in order to link with 
SM(PEG)12 modified transferrin as a model conjugate and utilize different mass 
spectrometric approaches to characterize the binding. ESI and MALDI mass 
spectrometry was performed on these two proteins individually, as well as conjugated 
together, to identify the location of the linkers in this highly heterogeneous mixture. 
Initially, quantification was performed by tryptic and chymotryptic digestion to measure 
the intensity of each peptide fragment to determine the relative binding frequency. This 
proved to produce difficulties, so other methods were explored, which included site-
specific modifications, 18O labeled digestion, creation of calibration curves, and 
online/offline IEC. Various parameters were altered in order to achieve the best results 
possible with hopes that future experiments can follow this works progress. 
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CHAPTER	  4	  
METHODS 
4.1 Preparation of Lz-Tf conjugate 
 Lysozyme from chicken egg white (Sigma-Aldrich, St. Louis, MO) was modified 
on its primary amine groups by N-succinimidyl-S-acetylthioacetate (SATA; Pierce 
Biotechnology, Rockford, IL). The reaction was performed by incubating for 90 minutes 
at 37°C in 50 mM phosphate buffer pH 7.0 consisting of 100 μM Lz with varying ratios 
of SATA ranging from 1:0.5 to 1:16 protein to reagent. Ideally, a 1:1 ratio would be 
preferred. Activation of human transferrin (provided by Prof. Anne B. Mason, University 
of Vermont College of Medicine) was performed by reacting succinimidyl-([N-
maleimidopropionamido]-dodecaethyleneglycol) ester (SM(PEG)12; Pierce 
Biotechnology, Rockford, IL) for 90 minutes at 37°C in 50 mM phosphate buffer pH 6.0 
consisting of 50 μM Tf and varying ratios of protein to reagent ranging from 1:1 to 1:4. 
Both reagents are prepared in DMSO and excess reagents were removed by using 5 kDa 
for Lz and 30 kDa for Tf centrifugal filters (Sartorius Stedim Biotech SA, Bohemia, NY). 
In order to deprotect SATA, for every 100 μL of modified protein solution, 10 μL of a 
solution of 0.5 M Hydroxylamine and 25 mM EDTA in 50 mM phosphate buffer should 
be added and allowed to incubate for 2 hours at room temperature. A 5 kDa filter can 
once again be used. The next step is to establish the noncleavable thio-ether linkage 
between the two activated proteins by incubating 50 μM of each modified protein in 50 
mM phosphate buffer pH 7.0 overnight in the fridge at 4°C. The reaction between Lz and 
Tf can be seen in the figure 4 above.  
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4.2 Mass Spectrometry  
 All electrospray ionization mass spectrometry measurements were performed on a 
QStar-XL (ABI/SCIEX, Toronto, Canada) hybrid quadrupole/time-of-flight MS fitted 
with either a nanospray or turbo spray source. An LC Packings Ultimate (Dionex/Thermo 
Fisher Scientific, Sunnyvale, CA) was used to combine LC/MS/MS. All MALDI mass 
spectrometry measurements were obtained using a microFlex TOF MALDI MS (Bruker 
Biospin Corporation, Billerica, MA). The matrix used for this method was α-cyano-4-
hydroxycinnamic acid (CHCA) saturated in 50:50 (v/v) water and acetonitrile with 0.1% 
trifluoroacetic acid (TFA). The samples were initially mixed with a 1:1 ratio of sample to 
matrix and 1 μL was pipetted onto a MALDI stainless steel plate and allowed to air dry. 
Calibration studies varied the amount of matrix and sample mixed before plating. The 
mass spectrometer was run in positive, reflectron mode that was optimized and calibrated 
prior to running samples.  
4.3 Ion-Exchange Chromatography 
 Weak cation exchange chromatography was performed on an Agilent 1200 
(Agilent Technologies, Palo Alto, CA) HPLC system using a 4.6 x 100 mm PolyCATA 
column (5 μM, 1000 Å, PolyLC inc., Columbia, MD). This column consists of silica-
based material with a bonded coating of polyaspartic acid. To separate Lz isoforms, a salt 
gradient was introduced with a starting buffer of 50 mM phosphate buffer pH 6.8 and 
buffer B consisting of 50 mM phosphate buffer with 0.4 M NaCl pH 6.8 using a flow rate 
of 0.4 mL/min. To separate Tf isoforms, a pH gradient was utilized by increasing the pH 
of 50 mM phosphate buffer from 5.5 to 7.5 using a flow rate of 1 mL/min.  
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4.4 18O labeling 
 This isotope labeling method utilizes trypsin’s ability to exchange both C-terminal 
oxygen atoms with labeled H218O oxygen atoms. When tryptic digestion takes place, it 
cleaves the carboxy side of lysine or arginine, and replaces these carboxy oxygen atoms 
with labeled ones, allowing the ability to run two samples at one time since the labeling 
will not change the chromatographic properties of the peptide and creates a 2- or 4-Da 
mass shift from the isotopic oxygen. After performing the digest of modified Lz and Tf, 
the sample is nitrogen or air dried until they are completely depleted of water. Once 
assured the sample is water free, water is added back into the sample by adding 45 μL of 
H218O (Sigma-Aldrich Chemical Co., St. Louis, MO) to the control sample and regular 
H216O to the modified sample. Then an additional 0.5 μL of trypsin and 5 μL of DMSO 
are added to allow incorporation to occur while incubating at 37°C for a day. When it 
comes time for analyzing the samples, figure 9 shows that normal tryptic cleavage will 
produce two separate peptide fragments (blue) to act as the control peptides. Once the 
protein is modified, trypsin can no longer cleave the modified lysine residue, meaning the 
spectra cannot show the modified peptide (red*). By comparing the cleavable peptides to 
the control, in this figures case, 70% to the 100%, it is clear that 30% of the abundance is 
lost, signifying the lost percentage went to the modified species, giving the ability to 
predict the amount modified per peptide. Looking at the mass spectra in the figure, a 
mass shift between 16O and 18O samples can be observed. The “I” values seen are the 
relative intensities, with I0 being the modified species, I2 being one incorporation of 18O 
and I4 showing a 4 Da mass shift representing our unmodified species. The “M” values 
are the expected relative intensities calculated by the analyst software used. In order to 
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determine the percent modified, a formula is used to find the ratio of 18O to 16O. Once the 
value of this formula ratio is found, the control ratio serves as the ro value and the 
modified ratio serves as the rm value in the next percent modified equation, which uses 
the control ratio over the modified ratio to give a percentage modified. 
 
Figure 9: This figure illustrates the 18O method. By using the control peptides, the percent 
modified can be calculated by introducing oxygen isotopes to modified species. By using 
the ratio of 18O/16O, the ro and rm values can be determined to finish the percent-modified 
equation. To the right is an example of the 4 Da mass shift between 18O and 16O labeled 
species. 
4.5 Site-Specific Modification 
 This site-selective method comes from an article by Weil et al. demonstrating 
their ability to control site modification.39 With this method, they claim to have created a 
method that allows site-specific modification of the N-terminal of the protein RNase A 
by using kinetic control conditions. The main idea behind this method is to add small 
amounts of reagent slowly over a long increment of time. A depiction of their experiment 
can be seen in the first figure of the article. They start with their control spectrum with 
RNase A alone showing a single peak with the correct m/z value of 13682. The next step 
involves adding the entire volume of reagent at one time with a 1:10 ratio of protein to 
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reagent. The spectrum shows a poor resolution of up to seven modified species. Next by 
decreasing the ratio of protein to reagent, the spectrum becomes cleaner and shows fewer 
and fewer modified species. The true experiment starts when they use a 0.5:1 reagent to 
protein ratio and divide the reagent into 100 equivalent portions added stepwise over a 
course of 100 minutes. The reactions are further continued for 1 hour after the final 
injection of reagent to ensure modification has the time to take place. The reaction is 
finally quenched with the addition of ethanolamine solution and incubated overnight in 
order to deactivate any remaining unreacted reagents. By using affinity chromatography, 
the modified peak was extracted and once digestion, proved to represent the N-terminal, 
being the solely modified species. 	  
A replication of this groups experiment was performed with Lz by using an 
automated syringe pump to add the SATA reagent to the protein solution at specific 
stepwise fashion. The first step is to create the Lz and SATA solution in separate vials, 
keeping in mind what ratio is desired and making slightly extra SATA solution to wash 
through the tubing connecting the syringe to the Lz solution. A 1 mL Lz solution was 
made using 50 mM phosphate buffer pH 7.0 and a 250 μL solution of SATA in DMSO 
was made. The method calls for adding 50 μL of reagent to the Lz solution, so the 
concentration of SATA had to be calculated differently each time a different ratio was 
desired. With the excess reagent solution, a thorough cleaning of the lines was performed 
beforehand to ensure that when it came time to injecting reagent, reagent was actually 
coming out of the line and not water or other unwanted solutions. Two samples with 1:4 
and 1:2 ratios of Lz:SATA were prepared and the SATA solution was added all at once 
or at a 5 μL/min rate with a stir bar constantly spinning. Once the reagent was added, the 
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solution spun for an extra hour to ensure the modification would take place. The stir plate 
created heat during the longer addition steps, so placing the Lz solution on top of a weigh 
boat allowed the reduction of any heat coming from the magnetic stir plate. This 
experiment had a goal of creating a single species of mono-modified protein. Lastly, a 
1:16 ratio was run at a 1 μL/min rate followed by immediate MS and IEC analysis to see 
how this increase in ratio and decrease in rate would affect the site-selection method.  
4.6 Antimicrobial Activity Assay 
 The bioactivity of Lz and modified Lz was measured using resuspended dried 
cells of Micrococcus lysodeikticus (Worthington Biochemical Corp., Lakewood, NJ) as 
the substrate. The rate at which the cell walls were lysed was measured in 0.1 M sodium 
phosphate buffer pH 7.0 at 25 °C using the transmission at 450 nm. All measurements 
were performed in a 1 mL cuvette with a NanoDrop 2000c (Thermo Fisher Scientific, 
Rockford, IL) UV-vis spectrophotometer. Percent activity of modified Lz species is 
measured against control Lz species.  
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CHAPTER 5 
RESULTS 
	  
 There are few and far between transferrin based therapeutics despite its promising 
capabilities of transporting therapeutic payloads across the blood brain barrier. This rarity 
can essentially be blamed on the complexity and heterogeneity of conjugating this carrier 
to a drug, which causes stress when it comes time for analytical characterization. The 
focus of this study is on characterizing and optimizing the conjugation of transferrin and 
lysozyme by the use of linkers SATA and SM(PEG)12. By characterizing the conjugate, 
the correlation between conjugation sites and efficacy of the drug can hopefully be 
determined. Transferrin alone has 58 lysine residues, which becomes the point of 
attachment in the conjugation; so trying to solve the optimal locations for the highest 
bioactivity or receptor binding is part of the goal for the overall large-scale project. 
Lysozyme has six lysine residues and the N-terminal amino group, making a total of 
seven locations for possible modification. Based on the model shown in figure 10, the 
locations of each lysine residue can be seen. As expected by the hydrophilic properties, 
all of the locations are located on the surface of the protein. The optimal location for 
modification is thought to be as far away from the catalytic site as possible so there is 
little interference with the bacteriostatic abilities of Lz. In order to try and solve the full 
conjugate problem, the challenge was broken into separate sections concentrated on 
solving the individual proteins first. This study goes through multiple methods in order to 
try to achieve every goal.  
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Figure 10: Lz surface showing locations of lysine residues (blue) and the activation site 
(red) that lyses bacterial cell walls (yellow). 
5.1 Lysozyme Modification 
 The first series of experiments mimicked previous studies by performing a tryptic 
digest in order to calculate peak intensities of individual peptides relating to a percentage 
of modification. Lz is first modified by decorating the free thiol groups with various 
concentrations of SATA by taking 100 μM Lz in 50 mM phosphate buffer at pH 7.0 and 
incubating for 90 minutes at 37°C. Excess reagents were removed by using a 5 kDa 
centrifugal filter. Since the first portion of these experiments focus on the 
characterization of the individual proteins, Lz does not need deprotection of SATA for 
conjugation quite yet. With Lz modified, a tryptic digest should produce modified and 
unmodified peptides. The digestion is performed by incubating 14.3 μg of Lz in 
denaturing buffer, which consists of 6M guanidine hydrochloride in 100 mM ammonium 
bicarbonate pH 8, for 1 hour at 37°C. Once the reaction is cooled to ambient temperature, 
alkylation occurs after reacting the Lz solution with 500 mM Iodoacetic acid for 30 
minutes in an ambient dark location. A buffer exchange of the protein from the matrix to 
50 mM phosphate buffer is performed through the use of centrifugation. Finally 0.5 μg of 
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trypsin is added and the solution is incubated overnight at 37°C. To ensure that SATA is 
properly attaching to Lz, a large ratio of reagent to protein was used. The specta in figure 
11 show that Lz is indeed being modified with SATA by having a mass addition of 116 
units. As the concentration of SATA is increased from 400 μM (1:4) to 3200 μM (1:32), 
the spectra show a correlated increase in Lz modification; to the point where all seven 
locations appear modified and the predominant species shifts from being singly modified 
to having 5 modified sites per Lz protein. It also appears that as the SATA ratio increases, 
singly or doubly modified Lz species disappear; which are the desired products needed in 
order to determine the specific sites SATA prefers to bind to. It should be noted that the 
smaller peaks to the right of each SATA peak are salt adducts from the buffer used. 
 
 
Figure 11: The MS spectra of different Lz:SATA ratios, showing the amount of 
modification that takes place as reagent is increased. 	  
  With the assurance that SATA will bind with Lz, the task of determining at which 
location does binding preference occur becomes the next focus. Through tryptic 
digestion, Lz will be chewed into smaller peptide fragments with cleavage points at 
lysine and arginine residues. When Lz is modified with SATA, the lysine residues are 
incapable of being cleaved; leaving specific peptides that can be used to calculate the 
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amount of modification at each individual lysine residue contained within the sequence. 
Utilizing a peptide sequence map to calculate correct masses of peptides that are cleaved 
at arginine sites and contain a modified lysine, Lz will have modified peptides 1-5, 6-14, 
22-45, 74-97, 97-112, and 115-125. Unmodified Lz can still be cleaved at both arginine 
and lysine residues. Each modified and unmodified peptide has a specific masses based 
on the amino acids and can be correlated to peaks on a mass spectra. After calculating the 
masses of those modified peptides; a mass addition of SATA (116 units) will give the 
correct modified mass. Using the intensities can give a percentage of modification by 
using the modified intensity divided by the total intensity of the modified and unmodified 
(no 116 mass addition peptide). Based on the mass spectra, the mass addition of the 
modified peak was not adding up to the expected 116 units, but instead was seen at +132 
units. An additional oxygen that was not expected can account this for. In figure 12, the 
modification scheme of Lz with SATA is depicted. Starting with the top left corner, 
SATA attaches to the primary amine group of Lz. Below that is the deprotection of the 
sulfhydryl group in preparation of binding Lz-SATA with the modified Tf. The sample is 
prepared for tryptic digest by adding iodoacetic acid for alkylation. The right half of the 
figure shows that when iodoacetic acid is added to a cysteine, which acts in this case as 
modified Lz, alkylation occurs and a mass addition of +132 appears on the mass spectra.  
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Figure 12: The scheme of how Lz is modified by SATA and activated by deprotection. 
When performing tryptic digestion, alkylation occurs with Iodoacetic acid. An example is 
given by using a cysteine residue. 	  
5.2 XIC Estimation of Lysozyme 
 After complete tryptic digestion, the Lz-SATA samples are ready to run on the 
LC-MS and peptides are verified by MS2. Then by using the peak intensity values, the 
percentage of modification per lysine residue can be computed. The XIC of the expected 
modified peptides for 1:4 and 1:8 Lz:SATA can be seen in figure 13 The blue peak is the 
unmodified peptide (mass of peptide without SATA) and the mass addition of 132 units 
is the red modified peak. Typically the unmodified peaks should not be observed because 
they would be the cause of a miscleavage, since trypsin would cleave at the lysine 
residues; but since the peptide desired has the mass of the unmodified plus SATA, it was 
decided to use these unmodified peaks to determine the baseline amount of miscleavage 
that happens naturally. After going through the data, there was difficulty observing peaks 
over 2500 m/z and some of the modified peaks had low detection, causing problematic 
situations when trying to calculate the percentages since just a small change in intensity 
lead to a large change in percentage. In the 1:8 Lz:SATA K1 spectra, observed is another 
mass addition of 132 from the already modified, meaning that there was a doubly 
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modified version of that peptide, which could be thought of as an extra modification 
somewhere else in the peptide. The first lysine residue does happen to have two 
modification sites as stated above; one at the N-terminal and the other on the lysine 
residue. 
 
Figure 13: The XIC for 1:4 (A) and 1:8 (B) Lz:SATA. The blue peaks depict the 
unmodified species and the red peaks are modified species. 	  
 While the spectra do not look ideal, the percentages were calculated and as seen 
in figure 14, the K1 peptide followed by K33 had the highest percentage of modification. 
An interesting observation happens when the unmodified peak has a similar relative 
intensity to the modified peak. When the peaks have similar relative intensity, the peptide 
has a difficult time becoming modified since the unnatural miscleavage is just as 
common as the modified peptide. The spectra that have their red modified peaks with 
greater relative intensity over the unmodified are the peptides with the higher chance of 
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being modified. This hypothesis of relative peak intensity can be looked into later on 
when the IEC experiments begin. Since it was difficult to observe m/z values over 2500 
and some smaller peptides with a higher charge, the thought of using chymotrypsin came 
to mind to see if this could help observe the missing peptides. 
 
 
Figure 14: The calculated percent modified for each individual lysine residue at 1:4, 1:8, 
and 1:32 Lz:SATA ratios under tryptic digest.  	  
Chymotrypsin cleaves peptides at residues containing aromatic ring such as 
tryptophan, tyrosine and phenylalanine. Below in figure 15  the modified lysine 
containing peptides that will be produced from the cleavage are seen.  
 
Figure 15: Lz peptide map for chymotryptic digest. The red underlined peptides are ones 
observed and the yellow are peptides not observed but needed. 
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The samples were run on the LC-MS and after verifying the peptides; their intensities 
were used to calculate the percent of modification for each modification site. The red 
underlines from figure 15 above indicate the modified peptides that were verified; while 
the yellow lines indicate peptides not observe in the spectra. The main troubles this 
method had were the inability to find a peptide containing lysine 13 and separate peptides 
for lysine 96 and 97. Based on what was found, figure 16 shows the XIC of Lz:SATA at 
a 1:4 ratio using chymotryptic digest and the percentages calculated from these spectra.  
 
Figure 16: The XIC of 1:4 Lz:SATA (left) and the percent modified from the lysine 
residues observed with chymotryptic digest (right). 	  
Desperate for quality results for the missing peptides, the thought of combining trypsin 
and chymotrypsin came into play. While at first this seemed like a decent idea and results 
looked promising, it was quickly realized that the combination was not going to work 
since trypsin and chymotrypsin will cleave one another and possibly create more havoc 
than good.  
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5.3 Transferrin Modification 
 Transferrin is the next part of the puzzle in this conjugation, but has proved to be 
the more troublesome piece. Transferrin binds to SM(PEG)12 in similar fashion to Lz and 
SATA, with the only real difference being the length of the linker. As seen in figure 17 
this time the mass difference between modified and unmodified peaks is 750 m/z.  
 
 
Figure 17: Mass spectrum of Tf and modified Tf, showing the mass difference from 
adding SM(PEG)12.  
5.4 XIC Estimation of Transferrin 
 Transferrin has proved too difficult of a protein for this simple tryptic digest 
method to figure out each percentage of modification. In fact, when looking at the 
peptides needed to solve this goal, there appears to be too many lysine residues in close 
proximity to one another. Based on the data deciphered, only a handful of peptides could 
be used; whose sequence can be found in the red underline in figure 18 of the Tf peptide 
map. The green lines show peptides that could not found based on their m/z values, but 
still contain a lysine residue needed to achieve the overall goal. Other problems arise, 
indicated with the blue and purple underlines, which either could not be seen simple 
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because of the large size or because of peptides with the same masses as another. Peptide 
42-50 has the same mass as peptide 594-602 and peptide 103-113 has the same as 297-
308. The yellow underlines are peptides observed, but were too difficult to verify because 
of low intensity values.  
 
Figure 18: Peptide map of Tf. The red underlined peptides are peptides confirmed by 
MS2, green underlined are peptides not observed, yellow underlined are peptides that 
were observed but not confirmed, and the purple underlined peptides are examples of 
problems faced by having same masses. 	  
From the four peptides confirmed from the 1:2 Tf:SM(PEG)12, it appeared that the first 
lysine containing peptide was highly modified based on the mass spectra. With the 
difficulties in both proteins, a new method was implemented, where the incorporation of 
an oxygen isotope is used.  
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Figure 19: XIC of 1:2 modified Tf peptides. The blue peaks are unmodified and the red 
peaks are modified Tf. 
5.5 18O Labeling 
 The new method involves the incorporation of 18O into both carboxyl oxygen 
atoms of the C-terminal amino acid mediated by trypsin. This is performed in the same 
way as the original tryptic digest method, but after digestion, the samples go through a 
nitrogen/air gas drying. Once the samples are completely dry and depleted of water, they 
are reconstituted with either 45 μL of H218O to the control sample or regular H2O to the 
modified sample. Control peptides are those that when properly cleaved, do not contain 
any lysine residues to be modified. The addition of 5 μL of DMSO and 0.5 μL of trypsin 
to both control and modified samples was done to compensate for trypsin losing 80% of 
its cleaving ability after a day. Afterwards, the solution is incubated at 37°C for a day. 
The initial method was changed during the reduction step to exclude the denaturing 
buffer of Gd.HCl and have ammonium bicarbonate instead. The incubation was also 
altered to 50°C because during the protein purification step to eliminate excess reagents, 
samples were losing protein with the centrifugal filters. By eliminating the Gd.HCl, there 
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is no need for the use of centrifugal filters in the digestion method, thereby possibly 
giving better results.  
5.6 18O Labeling of Lysozyme 
 18O labeling of Lz started by finding the control peptides (Figure 20). Running the 
Lz samples through the nanoLC-MS, the control peptides give the average ro value to use 
in the calculations for determining the percent modified.   
 
 
Figure 20: Peptide map of Lz. Red underlined peptides contain lysine residues and are 
needed for the rm values. Green underlined peptides are control peptides not containing a 
lysine residue and serve as the ro value. 	  
With a 1:4 ratio of Lz:SATA sample (figure 21), the three control peptides were averaged 
to give a value of ro = 1.09 ± 0.11. This number comes from using the ratio equation 
shown in the methods section and then averaging the three calculated values. To produce 
the denominator of the equation, the rm values for the seven modified peptides were 
calculated. The larger the rm value, the more modification is possible at the specific lysine 
in that peptide. The same experiment was done with a 1:8 ratio of Lz:SATA. For the 
control peptides, the ro2 (peptide 46-61) was noticeably lower than the other two, so this 
was accounted to be an error and determined to be an outlier. With the outlier gone, the 
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calculated ro value was 2.87 ± 0.1. Both Lz ratio samples agree in having the same 
peptide fragments as highly modified. Comparing the new isotopically labeled results 
with the old percent modification values seen from the XIC estimates in figure 22, there 
are some clear discrepancies when it comes to which lysine has more capability of being 
modified.  
 
 
Figure 21: The mass spectra of 1:4 (left) and 1:8 (right) Lz:SATA using the 18O labeling 
method. The top spectra represent the control peptides and the bottom spectra represent 
the modified species. Their calculated r-values are shown above each spectrum. 	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Figure 22: The percent modified for 18O labeling method (top) and the XIC estimate 
method (bottom) are shown for 1:4 and 1:8 Lz:SATA ratios. 
5.7 18O Labeling Calibration Curve 
	  
The 18O values indicate that there is actually negative modification at lysine 97. 
Knowing that this cannot be fact, gave rise to the possibility that the method is peptide 
dependent and varies with the degree of 18O incorporation depending on the amino acid 
residues. For this reason, the next step taken was to create individual calibration curves 
for each peptide; that way each peptide is its own control, leaving the variable of peptide 
dependence out of the equation. Each peptide will have two controls, the first being the 
simple 16O and 18O alone and the second being the 1:1 ratio, which gives the ro value. The 
ro and rm values ideally should be equal to 1, making the percent-modified equation equal 
to 0% modified. The ro value is equal to the 1:1 ratio, or the 0% modified. The rm value is 
the percent modified value in question. The goal of creating a calibration curve is to find 
an equation for the line of best fit and use this equation to predict the percentage of 
modification.  
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5.8 18O Labeling Calibration Curve of Lysozyme 
	   The	  same	  18O	  labeling	  procedure	  was	  followed,	  but	  the	  amount	  of	  16O	  species	  added	  to	  the	  sample	  was	  varied	  in	  order	  to	  create	  a	  standard	  calibration	  curve.	  After	  calculating	  the	  r0	  and	  rm	  values,	  as	  seen	  in	  figure	  23,	  the	  plot	  of	  these	  values	  creates	  an	  equation	  for	  the	  line	  of	  best	  fit.	  With the equation of a line (y = mx + b), the y value 
is the ro value and the x value is the percent modified. In the graph shown in figure 24, 
each peptide can have its own linear fit line and equation.	  
  
0 % 10 % 20 % 60 % 80 % 90 % Mod Lz 
Peptide Sequences 
 
1:1  0.9:1 0.8:1 0.4:1 0.2:1 0.1:1 1:1  
VFGR 2-5 0.58 0.80 0.97 1.59 4.14 5.15 0.93 
CELAAAMK 6-13 1.74 1.93 2.38 4.24 11.99 17.74 2.16 
(R)HGLDNYR 15-21 1.51 1.62 1.87 2.61 5.72 7.31 1.04 
GYSLGNWVCAAK 22-33 2.08 1.25 1.95 2.54 5.97 6.31 5.34 
FESNFNTQATNR 34-45 2.23 2.19 2.85 3.81 8.15 10.07 5.21 
(R)NTDGSTDYGILQINSR 46-61 4.39 2.82 4.30 5.45 10.40 14.94 1.53 
(R)WWCNDGR 62-68 1.20 1.21 1.47 2.15 4.39 5.49 1.40 
NLCNIPCSALLSSDITASVNCAK 74-96 9.88 28.25 22.43 11.82 15.77 45.45 8.52 
IVSDGNGMNAWVAWR 98-112 11.46 12.39 15.84 10.59 18.24 35.00 3.19 
GTDVQAWIR 117-125 1.92 1.63 2.18 3.20 8.74 12.43 5.37 
 
Figure 23: Standard calibration curve values for Lz. The r-values are observed as a 
percent modified and the last column is 1:1 modifed Lz. The peptides highlighted in 
yellow are the control peptides. 
 For examples, the top equation in the graph is for peptide 2-5 and the bottom 
equation in the graph is for peptide 117-125. Then by taking the normal 1:1 modified Lz, 
the ro value can be calculated. For example, by taking the peptide 2-5’s ro value of 0.93 
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and plugging this value in for y; solving for x gives an answer of 28.2% modified. There 
will obviously be some error for each individual peptide when using the equation; for 
instance, the 60% modified r0 value for peptide 2-5 ends up giving a result of 57.4%, 
leaving an error within 5%.  
 
Figure 24: Graph of the Lz calibration curve. After finding a line of best fit, the equation 
is used to determine the percent modified for each peptide. 	  
The standard equations created by the calibration curve from the 18O method gives 
comparable results with values calculated by using the old percent modified equation of 
dividing the 18O r value by the 16O r value (figure 25). There is still a problem with lysine 
96 and 97 when it comes to their ion counts being low and causing large errors in the 
calculations. 
y	  =	  -­‐0.0153x	  +	  1.507	  R²	  =	  0.94778	  
y	  =	  -­‐0.0055x	  +	  0.5898	  R²	  =	  0.93496	  
0	  0.2	  
0.4	  0.6	  
0.8	  1	  
1.2	  1.4	  
1.6	  1.8	  
2	  
0	   20	   40	   60	   80	   100	  
1/
r	  
va
lu
es
	  
Percent	  Modi]ied	  
Lz	  Calibration	  Curve	  
Peptide	  2-­‐5	  Peptide	  6-­‐13	  Peptide	  15-­‐21	  Peptide	  22-­‐33	  Peptide	  34-­‐45	  Peptide	  46-­‐61	  Peptide	  62-­‐68	  Peptide	  74-­‐96	  Peptide	  98-­‐112	  
	  54	  
 
Figure 25: The percent modified for 1:8 Lz:SATA using the standard calibration curve. 
The blue trace shows the calculated percent modified by using the percent-modified 
equation, while the red trace utilizes the equation of a line to calculate the percentage. 
5.9 18O Labeling of Transferrin 
 The same procedures were performed on Tf, but once again this large protein 
proved difficult and will need to be worked on more extensively in the future. It may be 
possible to use this method, but it will take a lot of man-hours to go through different 
MS2 data to decipher which lysine is being modified when there are multiple residues in a 
single peptide. The beginnings of the Tf portion of the study found r-values for several 
peptides, but many more could not be calculated.  
 Plotting the few calculated r-value into a graph to find a line of best fit gives some 
hope for solving each peptide in the future. Using the equation of a line, the percent 
modified for the few peptides are compared with the percent modified values without 
using the calibration curve (figure 26). Once again, some of the values come out as a 
negative modification and this can be explained the same way as in Lz, where the specific 
peptides had low intensities, so the small variations in interpreting the data results create 
large changes in value.  
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Figure 26: Percent modified for each observed Tf peptide. The blue trace shows the 
values calculated without the calibration curve and the red trace utilizes the line of best-
fit equation to calculate the percent modified. 
5.10 MALDI-MS 
 ESI-MS is not the only method capable of solving problems; MALDI-MS has the 
ability to produce similar results. Even though the project is aimed at specifically using 
ESI-MS, the use of MALDI-MS can help verify results. To prepare the 18O labeled 
calibration curve samples, the amount of 16O was varied once again while the 18O amount 
was kept at a constant.  
Ratio Stock A 
(uL) 
18O sample 
(uL) 
Matrix 
(uL) 
Total Volume 
(uL) 
1:1 5 1 0 6 
0.9:1 4.5 1 0.5 6 
0.8:1 4 1 1 6 
0.4:1 2 1 3 6 
0.2:1 1 1 4 6 
0.1:1 0.5 1 4.5 6 
  
Figure 27: Preparation for 16O sample to 18O sample for the MALDI calibration curve. 
The stock consists of a 1:4 16O sample to Matrix. 
 
A stock solution consisting of 5 μL of 16O sample and 20 μL of matrix (CHCA) was 
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added, keeping the 18O sample constant by adding only 1 μL. The 1:1 ratio was 
completed by adding 5 μL of stock and the constant 1 μL of 18O, leaving no room for any 
additional matrix. The 0.9:1 ratio took 4.5 μL of stock and 1 μL of 18O sample, leaving 
the remaining 0.5 μL consisting of matrix. The mass spectra for the control 1:1 mixtures 
can be seen in figure 28; where it is clear that the Lz is capable of being used in this 
method and Tf has some problems of overlapping peaks.  
 
Figure 28: The MALDI-MS spectra for Lz and Tf control species using the 18O labeling 
method. The Tf inset shows the troubles of overlapping peptides. 	  
Figure 29 shows the Lz calibration curve produced by the MALDI instrument and the 
percent modified calculated using the equation created with the linear trend line. There 
was some difficulty observing the larger peaks, which turned out to be the peptides most 
desperately needed since they contain the 96 and 97 lysine residues that had been giving 
trouble before. As before with the oxygen labeling method, lysine 33 and lysine 116 seem 
to have the most probability of being modified.  
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Figure 29: The calibration curve for Lz using MALDI-MS is depicted on the left, and the 
calculated percent modified using the line of best fit is shown to the right. 	  
 When it was time to run Tf samples with MALDI, only a handful of peptides 
could be fully interpreted because of overlapping peaks and low intensities. Comparing 
the values for the experimental percent modified against the theoretical percent modified 
shows nice linearity (figure 30. There is a possibility that if the instrument was highly 
optimized specifically for Tf, more interpretable peptides would appear; but strictly for 
time concerns, Tf samples were left for future work.  
 
Figure 30: Calibration curve for the few observed peptides of Tf. We arranged the data to 
show the theoretical % modified to the experimental % modified and are able to observe 
a relatively linear line. 
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 Although MALDI proved to be superior when it came to run time and precision, 
with each sample only taking about 1 minute for MALDI and about 100 minutes for ESI-
MS, the method could not resolve as many peptides as ESI-MS and would take time 
consuming optimization for each type of sample. With the difficulties faced up to this 
point of not being able to interpret all of the peptides, the experiment took a different 
route after discovering the research done by Weil et al. The thought that by taking this 
site specific approach could remove the heterogeneity by only allowing a single site to be 
conjugated, revealing the most prevalent location for binding. This would eliminate the 
need to probe each lysine residue since each protein would only have one specific linker 
site. 
5.11 Site-Specific Modification 
 In the paper, the authors claim to be able to specifically modify the N-terminal of 
the protein RNase A by using kinetic controlled conditions. In short, by injecting small 
portions of the reagent over time intervals, the concentration of reagent throughout the 
mixture is minimal, leading to sole binding at the optimal site. As mentioned in the 
methods section, the group showed how their approach worked by injecting at a ratio of 
0.5:1 reagent: protein at 100 different time intervals to achieve their mono-biotinylated 
RNase A. Following their idea, an automated syringe pump was used to slowly inject 
SATA into a solution of Lz at certain time intervals. To start the experiment, a 1:4 
Lz:SATA ratio (4eq) was created and the full amount of SATA was added to the Lz 
solution at one time (1-Portion). This is actually the normal procedure to create the 
modified Lz samples. From the MS, there is at least a tri-modified species observed (left 
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spectra figure 31). The next step was to halve the ratio and again add the entire amount of 
reagent at one time, leaving the MS to show at least a 2-SATA modified species. With a 
1:4 ratio, the amount of SATA added to the protein solution was split into portions to try 
and replicate the results of the authors. In total, there is 50 μL of reagent to add to the Lz 
solution, so the experiment added 5 μL every minute for a total of ten times. There is a 
noticeable difference between the two mass spectra of the control 1:4 sample performed 
at the start and this step-wise sample, with less locations being modified. The same step-
wise procedure was performed on a 1:2 ratio and once again the mass spectra shows less 
heterogeneity took place. With the MS data showing that there is still the presence of 
doubly modified species, it was decided to add less reagent per minute. To ensure there 
would still modification, a 1:16 ratio of Lz to SATA was prepared and had 1 μL of the 
reagent portion added every minute. The MS spectra in figure 31 shows that this slow 
addition of reagent did create a singly modified species, but unlike the original 
experiments, there was not sufficient yield of this site-specific species created even with 
an increased ratio of SATA. The experiments were performed on the bench top at room 
temperature; so there is a possibility that if the addition of reagent was done in a cold 
room that there could be a higher yield of mono-modified species.  
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Figure 31: The MS spectra for the site-selective method. The farthest left box shows a 1:4 
Lz:SATA ratio where all of the reagent was added at the same moment. Next is the same 
situation except a 1:2 ratio was used. Still moving right we see in the middle box the 1:4 
ratio, but this time the reagent was added in 10 equivalent portions. The next box is the 
same situation except with a 1:2 ratio. The last box is the using a 1:16 ratio and added 
reagent in 50 equal portions. 
5.12 Ion Exchange Chromatography of Lysozyme 
After performing the site specific method and seeing that adding the reagent 
slowly in small volumes can create a singly modified species, the next step is to check 
and see if the species was actually a single lysine modified or if there were different 
lysine residues modified. Instead of digesting this site-specific species, weak ion 
exchange chromatography was used to show us if it is solely one site-specific species or 
if there are multiple site-specific species created based on the chromatogram peaks. By 
running a salt gradient, the chromatogram clearly shows that the site-specific species was 
in fact different lysine residues modified. While this was a sad outcome in regards to not 
being able to modify a single lysine residue and leaving the others unmodified; an 
opportunity to see which species is more abundant based on the peak areas could brighten 
the situation. From figure 32 the 1:2 Lz:SATA site-specific sample had fewer species 
than the 1:4 ratio, so to be able to collect and identify these species, a larger ratio of 
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reagent would be wise, so the smaller peak species can be observed and collected to run 
offline ESI-MS to identify which elution peak corresponds to which lysine residue.  
 
Figure 32: Weak ion exchange chromatogram of Lz samples. The black trace is control 
Lz, the blue trace is 1:2 Lz:SATA using the site-specific method, and the red trace is a 
1:4 ratio using the site-specific method.  	  
 Since the site-specific experiments did not produce the same results as the 
previous lab, the next step was to collect fractions after isoform separation with IEC. 
When optimizing the conditions for the column by running multiple ratios of Lz to SATA 
samples; a noticable effect occurred when the pH of the buffer used in the modification 
was changed from 7.0 to 6.0. A lower yield of modified Lz was produced when we 
dropped the pH compared to the normal pH, meaning pH 7 is the optimal pH to try to 
collect fractions. Also shown in figure 33 are three different ratios of Lz:SATA and this 
shows how increasing the amount of reagent produces more multiply modified species. 
To the right of the chromatograms in the figure below are the MS spectra of each varied 
ratio sample, showing what is predominately produced from the increased ratio of 
reagent. The MS proves that the lower retention time peaks appear to be the more multi-
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modified Lz species, since the 1:3 ratio samples mostly showed singly modified and the 
1:12 ratio showed more triply modified species.   
 
Figure 33: The left chromatogram depicts the IEC of different Lz species. The right 
shows the MS spectra of the same Lz samples depicting the Lz-SATA species present. 	  
The MS spectra allowed us to make the observation that the lower retention time 
peaks were higher modified species, but there still was a need to identify what peaks 
actually correspond to which species. The long way of doing this is by collecting each 
peak and running offline MS to find out what is what, but an easier way is to run online 
MS and based on the m/z value, the spectra will tell exactly what species is 
predominantly in each elution peak. Going with the middle ground, a 1:8 Lz:SATA 
sample was run with the IEC-MS. The black trace in figure 34 shows the IEC 
chromatogram of the Lz-SATA sample. The large spike at the start is the solvent front 
and is mostly made from excess reagent and buffer. The red trace above the 
chromatogram is the MS spectra. The spectrum starts after the solvent front so damage 
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and salt build up is minimized on the MS instrument. Below both are the MS spectra 
based on what modified species is observed.  
 
Figure 34: This figure shows the IEC chromatogram in black and the MS spectra in red. 
Below are the different species of modified Lz, showing what peaks correspond to which 
modified species. 	  
As expected, the higher modified species elute out earlier than the mono-species. 
The data also shows that some peaks have overlapping species. With knowing where the 
mono-species are located on the IEC chromatogram, it is possible to collect these specific 
fractions in order to discover which lysine residue corresponds to which peak. This will 
provide the site-specific species that could not be created through the other methods. By 
identifying the specific location, the possibility of correlating each lysine residue with 
bioactivity can create a more potent and exact conjugate drug. Five fractions were 
collected, starting with F0 being the unmodified Lz sample and moving towards the 
lower retention time fractions 1-4. The most abundant modified peaks are fractions 1 and 
then 3, so hopefully by using the LC-MS each peaks corresponding lysine residues can be 
found, eluting to which site is the more likely binding sites on Lz. Fraction 1 contained 
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traces of both K96 and K97. Both may be found in the same peak because there is only a 
small difference in surface change when modified at these locations. There is a strong 
chance that the doubly modified species located between F1 and F2 (figure 35), around 
24 minutes, is Lz doubly modified with both K96 and K97, since the distance from 
unmodified to F1 to this doubly modified peak appears to have equal distances from each 
other. Fraction 2 consisted of K13 modified Lz and fraction 3 contained lysine 33 
modified Lz. Fraction 4 contained the K1 modified Lz species. The method was unable to 
observe even trace amounts of K116 in any of the collected fractions, leading to the belief 
that it is found somewhere else by co-eluting with multi-modified species. The results 
differ from Maiser et al. with regards to the location of the lysine residues as they elute 
off of the weak cation exchange column, but this could be explained by the different 
chemistry performed when modification occurs. Their lab was working with PEG linkers 
while the Lz in this experiment is modified with SATA. While both linkers attack similar 
residues; there is a difference in mass and surface charges. The results are somewhat 
similar to Lee et al. when it comes to K33 then K97 followed by K116 being the most 
predominate modification sites.  
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Figure 35: Shown is the chromatograms using IEC of the different Lz species after MS 
identified which species is present in which peak. Fraction 1 contained K96 and K97 
modified species, F2 contained K13 species, F3 contained K33 species, and F4 contained 
K1 modified Lz species. 
5.14 Bioactivity of Singly Modified Species 
 With the idea that modifying certain lysine residues may lead to different 
bioactivity of the protein, a photometric-based activity assay similar to what had been 
done before in the early experiments of this project was run. This experiment was 
performed more to see if the modification sites did produce any sort of difference; so the 
more probable sites were used since those are the sites most likely used in the future 
conjugation process. The three peaks were fractions: 0, 1, and 3. The initial results from 
the bioactivity assay used the unmodified collected peak as the control Lz sample and 
found that K33 had 49.9% activity and K96/K97 had 54.6% activity compared to the 
100% unmodified sample. Dividing the rate by concentration and then comparing this 
value to the control will give the overall percent of bioactivity. In figure 36, the graph 
shows the concentration of each Lz species determined by UV and their rate of cell wall 
F1 
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F2 
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lysis based on the slope of the line. The rate given for control Lz was 0.1928 a.u./min and 
the concentration of 5.6 μM was used. The rate for K33 was 0.1482 a.u./min and the 
concentration of 8.7 μM was used. The last fraction, with a concentration of 6.1 μM, had 
a rate of 0.1146 a.u./min.  
 
Figure 36: The bioactivity assay shows unmodified Lz in green, K33 modified Lz in blue, 
and K96/K97 modified Lz in red. Comparing rates to the control Lz, the percent activity 
can be calculated by taking rate over concentration.  	  
If these species were conjugated to Tf, then these activity values would decrease 
significantly. Future experiments will hopefully be able to determine where K116 is 
located and separate the K96 and K97 species to allow a full set of modified lysines for 
bioactivity testing. While these experiments will be conducted in the future to better 
characterize the novel drug, the near future will work on separating the isoforms of Tf-
SM(PEG)12 samples. 
5.15 Ion Exchange Chromatography of Transferrin 
 When running control Tf to observe the elution time of unmodified species, the 
chromatogram showed two peaks instead of one. The first thought that came up was the 
possibility that the transferrin was losing iron somehow and turning into Apo-Tf. A 
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sample of Apo-Tf was prepared by washing the stock Holo-Tf with 1mM EDTA in 3% 
acetic acid. The apo and holo control samples still showed small shoulders, meaning that 
the control still was not purely apo or holo (figure 37), but it was encouraging to see the 
second peak was indeed the other form of Tf.  
 
Figure 37: The chromatograms of apo-Tf and holo-Tf using IEC are shown. Ratios of 1:1 
and 1:2 protein to reagent show modified isoforms to be determined by MS in the future. 	  
From the chromatograms, it appears that holo-Tf has major isoforms, as seen with the 
multiple unresolved peaks in the 1:2 ratio sample. Apo-Tf looks as though there are not 
as many modified isoforms based on both chromatograms. If Tf is similar to Lz, then 
there can be the assumption that the first peak before unmodified species is a singly 
modified Tf. At this stage, it is unsure whether holo or apo Tf will produce a better result. 
It would be interesting to run a future experiment of using apo-Tf and once modification 
has occurred, replace iron back into the solution and use the mass spectrometer to see 
what comes of this.  
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CHAPTER 6 
CONCLUSION & FUTURE 
 
The amount of CNS infections appear to be sky rocketing, while the amount of 
small-molecule medicines capable of penetrating the BBB appear to be minuscule. With 
the fear of super bugs, antibiotic resistant pathogens, and the drastic side effects of 
inflammation immune responses ever growing, the urgency to develop novel 
biopharmaceuticals can no longer be ignored. Effective medicines starting to push their 
ways to the front lines of pharmaceutical research are chemically conjugated therapeutics, 
where a drug is bound to a transporter allowing specific delivery to target cells. The main 
reason why some of these awesome drugs have not yet reach any markets is because of 
their extreme complexity and heterogeneity that complicates the ability to characterize 
and create progress through the drug developmental processes. This work demonstrated 
that ESI-MS has the ability to provide characterization for a Lz-Tf conjugate. 
 The ability to determine the exact modification site for each of the conjugated 
proteins can hopefully later lead to the ability to correlate conjugation sites with 
bioactivity of the drug. Throughout the work, multiple methods were performed to try 
and predict the locations of modification for Lz and Tf. The first method performed was a 
tryptic digestion of modified Lz and Tf to run on nanoLC-MS-MS. Peptide fragments 
were searched for on analyst software and their intensities were used to determine a 
percent modified compared to the unmodified peptide peaks. This method had worked for 
others, but the current experiments had problems of low intensities and missing peptide 
fragments needed to truly calculate a trustworthy answer. The results showed that Lz was 
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mostly modified at the N-terminal and least likely modified at lysine 96. To try and 
overcome these problems, chymotrypsin was used as an alternative to digest samples, but 
once again had difficulty coming to a consensus answer. Transferrin showed a great deal 
more of trouble when digested because there were a great number of lysine residues that 
had the possibility of being modified and finding peptides that contained only one lysine 
residue was extremely difficult.  
 A new method was employed to help characterize the modified proteins with 
more accuracy. This 18O labeling method involved the normal digestion steps, but 
included a little extra by incorporating the isotopic water into both carboxyl oxygen 
atoms to create a specific mass shift that can be detected by the mass spectrometer. This 
method allowed for the comparison of two samples in a single run, which helps a great 
deal with limiting variability between samples. This method relies on the fact that 
incorporating the isotopic species will not change the chromatographic properties of the 
peptides. By using peptides that did not contain any lysine residues, the amount of 
incorporation that takes place in modified and unmodified control peptides was 
calculated by using the ratio of 18O over 16O. Using the ro values of the control peptides, it 
was discovered that lysine 33 of Lz appeared to be the most modified species, followed 
by K116. This differed from the original XIC estimates greatly, which had the N-terminal 
being the most heavily modified. Even this isotopic incorporated method had difficulty in 
observing clearly resolved spectra for all of the lysine residue peptides though. In 
noticing that the 1:8 Lz:SATA control peptides did not all have relatively similar ro 
values, the belief that there is a possibility that the oxygen labeling is peptide dependent 
came about.  
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 The way to get around peptide dependent labeling is to use each peptide as an 
individual control, eliminating the need to compare different peptides to each other. By 
creating a standard calibration curve, a line of best fit can be set to allow the percent 
modified to be calculated by simply inputting the rm value into the equation of a line for 
each specific peptide. This method gave a little more comfort in providing percentages of 
modification for each lysine residue, even though there was still difficulty with finding 
the K96 and K97 peptide masses. These calibrated results showed that K33 and K116 are 
highly modified compared to the other lysine residues. Trying this method out with Tf 
showed once again that large proteins with dozens of lysine residues in close proximity 
creates problems when finding proper peptide masses.  
 Lysine residues 96 and 97 had been showing problems when it came time to 
finding their modified peptides. MALDI is another instrument utilized for observing 
peptide masses, but is only capable of producing +1 charged state species and this 
characteristic lead to problems with overlapping peptides. Lysozyme is a small enough 
protein that overlapping peptides did not create an issue, but once again the larger peptide 
fragments containing K96 and K97 were elusive. With the use of a calibration curve, the 
MALDI results related nicely with the ESI results by having K33 and K116 being the 
most probable sites for modification, but MALDI had each of these peptides modified by 
at least an extra 10%. MALDI could prove helpful when it comes to characterizing 
smaller proteins like Lz with the ability to run numerous samples extremely quickly 
(almost 100x quicker) when compared to the LC-MS method used in this study, but the 
MALDI method proved little help when it comes to larger proteins because of the many 
overlapping peptides observed in Tf samples.  
	  71	  
 The difficulty of finding each peptide in the mass spectrometer lead to a new 
method of trying to create a single modified site by introducing the reagents in small 
portions over long periods of time. This site-selective method proved to work for other 
groups and would have hopefully produced just a singly modified lysine species to finally 
prove which residue has the greatest chance of being modified. After slowly adding 
SATA every minute for 100 minutes to complete a ratio of 1:16 Lz:SATA, the results 
produced were disheartening. Although the MS showed that singly modified species was 
indeed being created, the yield of this species was dismal and running the samples on IEC 
proved that there was not just a single lysine modified, but in fact multiple isoforms 
created.  
 Observing that the site-selective method still created isoforms of Lz, it was 
decided to take advantage of that property to collect the separate isoforms. Utilizing the 
ability of weak cation exchange chromatography to separate isoforms of the modified 
species, online IEC was used to determine where the mono-modified species were 
located and those peaks were collected to try and help in characterization. Discovering 
where the singly modified species were located, the samples were run offline through the 
nanoLC-MS to determine which lysine residue corresponded to which chromatographic 
peak. Four singly modified peaks were identified using the MS spectra, with K33 and 
K96/K97 being the most abundant modified species for Lz. Peptides containing K96 and 
K97 could not be separated because of similar surface profiles when modified and there 
was no detection of the peptide containing K116, which the past results showed to be a 
dominant species, so this was discouraging to not have complete results.  
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 Collecting specific lysine modified species allowed the ability to run bioactivity 
assays for each Lz species to see if modifying different lysine residues changed the 
bioactivity significantly. When compared to the unmodified species, it was found that 
K33 and K96/K97 had about 50% of the ability to lyse bacterial cell walls. The values 
were expected to be lower than the unmodified Lz species because the surface of Lz is 
being distorted and SATA may move in the way of the activation site cavity, hindering 
the ability to properly grab the cell wall and destroy the bacteria. This was a preliminary 
experiment using the highly modified species, where hopefully in the future these species 
can run with the Tf portion attached to get a full table of how this modified site correlates 
to the amount of bioactivity. Once Tf is attached, the bioactivity will surely decrease as 
Tf creates a much larger hindrance on Lz’s activity.  
 IEC experiments with Tf were conducted with the hopes of seeing how many 
isoforms are created, allowing an estimate of how many peptides truly need to be 
searched for on the LC-MS. Initial results appear to show that apo- and holo-Tf are 
modified differently, and although the drug will be using a holo-form to bind to the 
receptor, studies on apo-form could prove insightful.  
 As seen through the overview of results, this project still has a lot to do in the 
future. The continued work on characterizing Tf and then the actual Lz-Tf conjugate 
remains the biggest project remaining. The possibility of utilizing new and longer linkers 
could prove to increase the bioactivity of Lz, as the hindrance from Tf would likely 
decrease as more space is created between the two proteins. The stability of the conjugate 
is yet another study to be performed in the future. Knowing exactly how long the 
conjugate will stay bound and if the activity or receptor recognition decreases over time 
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is essential. None of these decreases are expected to happen since the conjugate is 
forming disulfide bonds, so the conjugate should stay stable over a long period of time. 
Understanding how much of the conjugate actually reaches the brain and any other 
locations within the body is critical as well. Recent efforts to create large amounts of 
conjugate has allowed the study to move forward with rat injections to determine the 
drugs migration pattern and if enough can pass through the blood-brain barrier to support 
its role in effectively killing targeted bacteria. Initial studies seem to show that while the 
amount entering the brain is small, this concentration is enough to perform the task asked 
of it.  
 A bevy of mass spectrometric-based methods have been performed in this work to 
help characterize the conformational integrity of the model bacteriostatic protein 
lysozyme and it’s transporter protein transferrin. The steps taken to achieve the goal of 
determining modification sites of both proteins can hopefully one day be used to create 
more advanced conjugate biopharmaceuticals. Till that day, the work discussed in this 
thesis will continue to be optimized to provide a model system for future medicines.  
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